Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Infectious Disease

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777917

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1777917

Carbapenem

PUBLISHED:
PAGES: 383 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 5850
PDF (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Carbapenem Market to Reach US$4.7 Billion by 2030

The global market for Carbapenem estimated at US$3.8 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2024-2030. Meropenem Drugs, one of the segments analyzed in the report, is expected to record a 4.2% CAGR and reach US$2.1 Billion by the end of the analysis period. Growth in the Imipenem Drugs segment is estimated at 3.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.0 Billion While China is Forecast to Grow at 6.7% CAGR

The Carbapenem market in the U.S. is estimated at US$1.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$945.4 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.4% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Carbapenem Market - Key Trends & Drivers Summarized

Why Is the Demand for Carbapenem Antibiotics Increasing?

Carbapenems are a critical class of β-lactam antibiotics used to treat severe bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens. As antimicrobial resistance (AMR) becomes a growing global health threat, carbapenems are increasingly being relied upon as last-resort antibiotics for hospital-acquired infections, sepsis, pneumonia, and complicated urinary tract infections (cUTIs). The rising incidence of drug-resistant bacteria, including carbapenem-resistant Enterobacteriaceae (CRE), Pseudomonas aeruginosa, and Acinetobacter baumannii, has fueled the demand for these potent antibiotics in both developed and developing healthcare systems.

The increasing prevalence of nosocomial infections, particularly in intensive care units (ICUs) and immunocompromised patients, has further driven the need for carbapenem-based treatments. As healthcare providers seek more effective solutions for life-threatening infections, pharmaceutical companies are expanding their portfolios of carbapenem antibiotics, either as monotherapies or in combination with β-lactamase inhibitors to combat resistance. With the continued rise of AMR and the global push for stronger infection control measures, the demand for carbapenem antibiotics is expected to grow significantly.

How Are Technological Advancements Improving Carbapenem Efficacy and Development?

Innovations in pharmaceutical research and drug formulation are enhancing the efficacy, stability, and resistance-fighting capabilities of carbapenem antibiotics. One of the most notable advancements is the development of novel carbapenem-betalactamase inhibitor (BLI) combinations, such as meropenem-vaborbactam and imipenem-relebactam, which effectively target resistant bacterial strains. These combination therapies have demonstrated superior efficacy against carbapenem-resistant Enterobacteriaceae and other difficult-to-treat pathogens, making them essential in hospital settings.

Another key breakthrough is the use of nanotechnology and targeted drug delivery systems to improve the pharmacokinetics of carbapenem formulations. Liposomal encapsulation and other advanced delivery mechanisms are being explored to enhance drug penetration into infected tissues while reducing toxicity and side effects. Additionally, AI-driven drug discovery platforms are accelerating the identification of novel carbapenem analogs with improved antibacterial activity and reduced resistance potential. With continuous advancements in formulation and drug design, the next generation of carbapenem antibiotics is expected to offer enhanced potency, broader spectrum activity, and improved resistance management.

Which Market Trends Are Driving Growth in the Carbapenem Industry?

The increasing global burden of antimicrobial resistance (AMR) is one of the most influential trends shaping the carbapenem market. As infections caused by multidrug-resistant bacteria continue to rise, hospitals and healthcare systems are prioritizing the use of carbapenems in their antimicrobial stewardship programs. Governments and regulatory bodies, such as the FDA, EMA, and WHO, are actively promoting research and development in novel antibiotic therapies, leading to increased investments in carbapenem-based drug development.

Another key trend influencing market growth is the expansion of generic carbapenem production, particularly in emerging markets. As patents on branded carbapenem antibiotics expire, pharmaceutical companies in regions such as India, China, and Brazil are ramping up the production of affordable generic formulations, making these life-saving antibiotics more accessible in low- and middle-income countries. Additionally, the rise of hospital-acquired infections (HAIs) and the increasing number of immunocompromised patients undergoing complex medical procedures are driving higher carbapenem usage worldwide. With the growing emphasis on combating AMR, global demand for both branded and generic carbapenems is expected to rise.

What Are the Key Growth Drivers Shaping the Future of the Carbapenem Market?

The growth in the carbapenem market is driven by several critical factors, including the rising prevalence of drug-resistant bacterial infections, increasing hospital admissions, and advancements in antibiotic combination therapies. One of the primary growth drivers is the urgent need for effective treatment options against Gram-negative bacteria, which have shown increasing resistance to conventional antibiotics. As healthcare providers struggle to manage severe infections, carbapenems remain an essential component of antimicrobial therapy.

Another crucial driver shaping the market is the expansion of government and private sector funding for antibiotic research and development. Global health organizations and pharmaceutical companies are investing in innovative carbapenem formulations and resistance-fighting drug combinations to address the AMR crisis. Additionally, regulatory approvals for next-generation carbapenem-BLI combinations are expected to accelerate market growth, providing healthcare professionals with more targeted and effective treatment options. As the fight against AMR continues, the carbapenem market is poised for sustained expansion, driven by innovation, increasing demand for hospital-based treatments, and global efforts to preserve the effectiveness of last-resort antibiotics.

SCOPE OF STUDY:

The report analyzes the Carbapenem market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs, Other Drug Classes); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Other Distribution Channels); Application (Urinary Tract Infections Application, Bloodstream Infections Application, Intra-abdominal Infections Application, Pneumonia Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • ALPS Pharmaceutical Ind. Co., Ltd.
  • AstraZeneca plc
  • Asymchem Laboratories Inc.
  • Aurobindo Pharma Ltd.
  • Beijing Lunarsun Pharmaceutical Co., Ltd.
  • Daewoong Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • Fresenius Kabi LLC
  • GlaxoSmithKline plc
  • High Science Co., Ltd.
  • Jeil Pharmaceutical Co., Ltd.
  • Meiji Holdings Co., Ltd.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Pharma Impex Laboratories Pvt. Ltd.
  • Sandoz International GmbH
  • Shionogi & Co., Ltd.
  • Spero Therapeutics
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP29810

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Carbapenem - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Multidrug-Resistant Infections Throws the Spotlight on Carbapenems as a Last-Resort Therapy
    • Escalating Global Antimicrobial Resistance (AMR) Crisis Propels Demand for Broad-Spectrum Carbapenem Antibiotics
    • Increasing Hospital-Acquired and ICU Infections Expands the Addressable Market for Carbapenem-Based Treatments
    • Surge in Gram-Negative Bacterial Infections Strengthens the Business Case for Carbapenem Usage in Critical Care
    • Growing Demand for Combination Therapies Drives Innovation in Carbapenem-Beta-Lactamase Inhibitor Products
    • Regulatory Push for Novel Antibiotic Development Fuels R&D in Next-Generation Carbapenem Analogs
    • Expansion of Hospital Formulary Listings and Stewardship Programs Enhances Clinical Access to Carbapenems
    • Increased Adoption in Emerging Markets Accelerates Global Market Penetration for Generic Carbapenem Brands
    • Pharmaceutical Industry Focus on Injectable Anti-Infectives Spurs Demand for Carbapenem Formulations
    • Rising Surgical Procedures and Immunocompromised Patient Populations Drive Empirical Use of Carbapenems
    • Patent Expiries and Generic Competition Drive Down Prices While Expanding Volume-Based Opportunities
    • Growing Carbapenem-Resistant Enterobacteriaceae (CRE) Incidence Creates Urgency for Stewarded Use and Alternatives
    • Rapid Diagnostic Advancements Enhance Targeted Use and Optimize Carbapenem Prescribing Practices
    • Increased Focus on Carbapenem Stewardship and Surveillance Systems Presents Both Regulatory and Market Challenges
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Carbapenem Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Carbapenem by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Meropenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Meropenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Meropenem Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Imipenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Imipenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Imipenem Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Ertapenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Ertapenem Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Ertapenem Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Intra-abdominal Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Intra-abdominal Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Intra-abdominal Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pneumonia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pneumonia Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pneumonia Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Urinary Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Urinary Tract Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Urinary Tract Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Bloodstream Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Bloodstream Infections Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Bloodstream Infections Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 41: USA Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 47: USA Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Carbapenem by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 89: France Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 95: France Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 116: UK Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 122: UK Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Carbapenem by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 173: India Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 179: India Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Carbapenem by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Carbapenem by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Carbapenem by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Carbapenem by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Carbapenem Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Carbapenem by Drug Class - Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Carbapenem by Drug Class - Percentage Breakdown of Value Sales for Meropenem Drugs, Imipenem Drugs, Ertapenem Drugs and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Carbapenem by Application - Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Carbapenem by Application - Percentage Breakdown of Value Sales for Intra-abdominal Infections Application, Pneumonia Application, Other Applications, Urinary Tract Infections Application and Bloodstream Infections Application for the Years 2015, 2025 & 2030
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Carbapenem by Distribution Channel - Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Carbapenem by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!